Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List

详细摘要

PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,…

PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfully included in the updated National Reimbursement Drug List (2026) (the "NRDL").

Products included in the NRDL for the first time include mazdutide (a GCG/GLP-1 dual receptor agonist), PECONDLE® (picankibart injection, an IL-23p19 inhibitor), TABOSUN® (Ipilimumab N01 injection, a CTLA-4 inhibitor), and Vanflyta® (quizartinib, a Type II FLT3 inhibitor). Products with newly added indications included in the NRDL comprise TYVYT® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jaypirca® (pirtobrutinib, a non-covalent BTK inhibitor); and SINTBILO® (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The updated NRDL will officially take effect from January 1, 2027.

Dr. Michael Yu, the Founder, Chairman of the Board and CEO of Innovent, stated: "We are highly pleased that the seven innovative drugs of Innovent have been successfully included in the National Reimbursement Drug List this time, covering disease areas with heavy societal burdens such as oncology (colon cancer, renal cancer, and hematological malignancies), cardiovascular and metabolic diseases, as well as autoimmune diseases. The inclusion of the innovative drugs in the NRDL will further enhance the accessibility and affordability for patients, allowing more of the public to benefit.

MazdutideInnovent entered into an exclusive license agreement with Eli Lilly and Company for the development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China.

文章开头，摘自PR Newswire。如需阅读全文，请前往媒体网站。